APG Asset Management N.V. Raises Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• APG Asset Management N.V. increased its holdings in BioNTech SE by 5.8% in Q1, owning 49,600 shares worth $4.18 million as of its latest SEC filing.
• Other institutional investors also significantly boosted their stakes, with Bank of New York Mellon Corp increasing its holdings by an extraordinary 18,892.9% during the same quarter.
• BioNTech's stock currently has a consensus rating of "Moderate Buy" among analysts, with a target price of $135.80.

APG Asset Management N.V. raised its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,600 shares of the company's stock after acquiring an additional 2,700 shares during the quarter. APG Asset Management N.V.'s holdings in BioNTech were worth $4,181,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Banque Cantonale Vaudoise acquired a new position in BioNTech in the 1st quarter valued at about $36,000. Costello Asset Management INC acquired a new position in BioNTech in the 1st quarter valued at about $91,000. Goodman Advisory Group LLC acquired a new position in BioNTech in the 1st quarter valued at about $105,000. Tower Research Capital LLC TRC grew its position in BioNTech by 61.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after acquiring an additional 713 shares in the last quarter. Finally, Probity Advisors Inc. grew its position in BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after acquiring an additional 154 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Down 1.9%

BNTX traded down $1.93 on Friday, reaching $100.00. The company's stock had a trading volume of 505,409 shares, compared to its average volume of 775,852. The stock has a 50 day moving average of $109.66 and a two-hundred day moving average of $105.08. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.04 billion, a price-to-earnings ratio of -62.50 and a beta of 1.23. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period last year, the company earned ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts forecast that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the subject of several research reports. Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. Bank of America boosted their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $135.80.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.